Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.78 |
| ▸ | NT5E | P21589 | 1/20 | 0.78 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.78 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.77 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.77 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.75 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.73 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.73 |
| ▸ | DPP4 | P27487 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.72 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.72 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.72 |
| ▸ | GAPDH | P04406 | 1/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.72 |
| ▸ | STAT6 | P42226 | 1/20 | 0.72 |
| ▸ | PI4KA | P42356 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16579288 | 1.00 | LMNA (0.78) | LMNANT5EHIF1AADORA2AADORA3 | |
| SCHEMBL10176676 | 1.00 | LMNA (0.78) | LMNANT5EHIF1AADORA2AADORA3 | |
| SCHEMBL20419174 | 1.00 | LMNA (0.78) | LMNANT5EHIF1AADORA2AADORA3 | |
| SCHEMBL3741590 | 1.00 | LMNA (0.78) | LMNANT5EHIF1AADORA2AADORA3 | |
| SCHEMBL7168927 | 1.00 | LMNA (0.78) | LMNANT5EHIF1AADORA2AADORA3 | |
| SCHEMBL10159432 | 1.00 | LMNA (0.78) | LMNANT5EHIF1AADORA2AADORA3 | |
| SCHEMBL24359132 | 1.00 | LMNA (0.78) | LMNANT5EHIF1AADORA2AADORA3 | |
| SCHEMBL114918 | 1.00 | LMNA (0.78) | LMNANT5EHIF1AADORA2AADORA3 | |
| SCHEMBL22559823 | 1.00 | LMNA (0.78) | LMNANT5EHIF1AADORA2AADORA3 | |
| SCHEMBL440329 | 1.00 | LMNA (0.78) | LMNANT5EHIF1AADORA2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664195-B2 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2014-03-04 | — | — | US | claimed |
| US-7214668-B2 | Phosphonic acid based prodrugs of PMEA and its analogues | METABASIS THERAPEUTICS, INC. (US) | 2007-05-08 | — | — | US | claimed |
| US-7148349-B2 | Cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2006-12-12 | — | — | US | claimed |
| US-4038479-A | AMINO PURINE DERIVATIVES | BURROUGHS WELLCOME CO. (US) | 1977-07-26 | — | — | US | claimed |
| JP-58081794-A | — | — | None | — | — | JP | disclosed |
| CN-114630911-B | Enzymatic process for the preparation of UDP-GlcNAc | 马克斯·普朗克科学促进学会 | 2024-06-28 | — | — | CN | disclosed |
| WO-2024082546-A1 | METHOD FOR BIOSYNTHESIS OF ARABINONUCLEOSIDE BY ONE-POT METHOD, AND COMPOSITION | 凯莱英生命科学技术(天津)有限公司 | 2024-04-25 | — | — | WO | disclosed |
| EP-3874056-B1 | ENZYMATIC METHOD FOR PREPARATION OF UDP-GLCNAC | MAX PLANCK GESELLSCHAFT (DE) | 2023-06-14 | — | — | EP | disclosed |
| CN-115896215-A | Method and composition for one-pot biosynthesis of arabinoside nucleosides | 凯莱英生命科学技术(天津)有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-114630911-A | Enzymatic process for the preparation of UDP-GlcNAc | 马克斯·普朗克科学促进学会 | 2022-06-14 | — | — | CN | disclosed |
| US-20180214464-A1 | METHODS OF TREATING RETROVIRAL INFECTIONS AND RELATED DOSAGE REGIMES | CHIMERIX, INC. | 2018-08-02 | — | — | US | disclosed |
| CN-108210502-A | Treat the method for retroviral infection and relevant dose scheme | 奇默里克斯公司 | 2018-06-29 | — | — | CN | disclosed |
| EP-0311107-A2 | Anti-HIV active 3'-fluoro-purine-2',3'-dideoxyribosides | Stichting REGA V.Z.W. (BE) | 1989-04-12 | — | — | EP | disclosed |
| EP-0311108-A2 | Anti-HIV active 3'-azido-2,6-diaminopurine-2',3'-dideoxyriboside | Stichting REGA V.Z.W. (BE) | 1989-04-12 | — | — | EP | disclosed |
| JP-S5881794-A | PREPARATION OF 9-BETA-D-ARABINOFURANOSYLGUANINE | YAMASA SHOYU CO LTD | 1983-05-17 | — | — | JP | disclosed |
| US-4315920-A | Adenosine deaminase inhibitors | BURROUGHS WELLCOME CO. (US) | 1982-02-16 | — | — | US | disclosed |
| EP-0002192-B1 | ENZYMATIC SYNTHESIS OF PURINE ARABINONUCLEOSIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1981-11-04 | — | — | EP | disclosed |
| US-4136175-A | PURINE NUCLEOTIDE ANTIVERAL COMPOSITION AND METHODS OF USE | BURROUGHS WELLCOME CO. (US) | 1979-01-23 | — | — | US | disclosed |
| US-4081534-A | Amino purine nucleosides as autoimmune suppressant agents | BURROUGHS WELLCOME CO. (US) | 1978-03-28 | — | — | US | disclosed |
| US-4038479-A | AMINO PURINE DERIVATIVES | BURROUGHS WELLCOME CO. (US) | 1977-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180214464-A1 | METHODS OF TREATING RETROVIRAL INFECTIONS AND RELATED DOSAGE REGIMES | TPMT, HAVCR2, REV1 | LMNA 3908/4885NT5E 1344/4885HIF1A 2245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.